WO2006021843A1 - A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures - Google Patents

A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures Download PDF

Info

Publication number
WO2006021843A1
WO2006021843A1 PCT/IB2005/002199 IB2005002199W WO2006021843A1 WO 2006021843 A1 WO2006021843 A1 WO 2006021843A1 IB 2005002199 W IB2005002199 W IB 2005002199W WO 2006021843 A1 WO2006021843 A1 WO 2006021843A1
Authority
WO
WIPO (PCT)
Prior art keywords
casein
iron
succinyl
acetyl
solution
Prior art date
Application number
PCT/IB2005/002199
Other languages
French (fr)
Inventor
Sacchetti Alessandro Lapini
Original Assignee
Biofer S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofer S.P.A. filed Critical Biofer S.P.A.
Priority to EP05761444A priority Critical patent/EP1776382B1/en
Priority to DE602005011451T priority patent/DE602005011451D1/en
Publication of WO2006021843A1 publication Critical patent/WO2006021843A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732Casein

Definitions

  • the aim of the invention is to provide an industrial process for production of iron succinyl casein and acetyl-aspartate iron casein based complexes in which the substance is little exposed to pH and temperature conditions which might damage the protein's secondary, tertiary and quaternary chemical- physical characteristics, as well as facilitating preparation of the relative liquid pharmaceutical formulations and their appearance as clear solutions.
  • the process is also easy to realise industrially and is simpler with respect to other known processes.
  • Background Art Iron plays a fundamental role in both human and animal physiology.
  • the invention relates to a process for obtaining iron succinyl casein and acetyl-aspartate iron casein complexes, obtained by reaction of high-quality casein, for pharmaceutical use, with succinyl anhydride and iron chloride or with acetyl aspartic anhydride and iron chloride.
  • the process described for obtaining iron complexes with succinyl casein and acetyl-aspartate casein is characterised in that: a) the succinyl casein, iron succinyl casein, acetyl-aspartate casein and iron acetyl-aspartate casein obtained are damp-granulated when they are destined for further dissolving, to facilitate the dissolving process in water with addition of caustic soda with a pH of below eleven. b) The purified iron succinyl casein and acetyl-aspartate iron casein complexes obtained are dried using a spray drier.
  • the spray-drier is a frequently used machine in the food industry, especially in milk-derivative products which include casein.
  • the spray-drier technique is used in the pharmaceutical industry whenever a heat-sensitive product is to be dried.
  • the solution containing the iron casein complexes is reduced to very small droplets which are then dried by means of hot air which is directed onto the small droplets.
  • the powders thus obtained are collected in a separator centrifuge and then in a suitable container.
  • the solution containing the iron casein complexes can be freeze-dried. Freeze drying is obviously very gentle in terms of exposing the product to high temperatures. It is, however, an expensive process and is in general used for high-value products, almost always destined for use in the form of injections.
  • Overall the process of synthesis of the iron succinyl casein and iron acetyl- aspartate casein complex comprises the following steps:
  • step 2 can be purified by pulping in water or alternatively by dissolving in water and caustic soda at a pH of less than 1 1, followed by a further precipitation at pH 2.5 to 3.
  • the iron succinyl casein or iron acetyl-aspartate casein complexes are then dissolved in water with the help of caustic soda at a pH of less than 11 , preferably less than 9, and are then added to by suitable preservatives
  • Example no. 1 Production of iron succinyl casein complex. Step a) Succinylation of casein
  • step a) The solution obtained in step a) is transferred into a glaze reactor, equipped with a high-speed shaker to keep the solution homogeneous. This solution is slowly added to with 16-17 litres of HCl at 15% w/v up until a pH of about 3 is obtained. On reaching the correct pH addition of acid is stopped and a precipitate without salt and water-soluble impurities is obtained. Step c) Filtration and granulation.
  • the succinyl casein obtained in step b) is collected by filtration and washed with distilled water.
  • the product gathered from the filter is generally conformed in compact blocks which dissolve with difficulty. To facilitate dissolving damp granulation (e.g. in a Viani granulator) of the filtered product is recommended.
  • the granulate is placed in a stainless steel reactor in which 300 litres of distilled water have been placed, and the mixture is shaken until a homogeneous suspension is obtained, to which about 7 litres of caustic soda at 15% w/v are added up until a pH of 8-9 is reached. During the final stage the suspension is shaken for about 6 hours in order to obtain an almost- complete dissolving of the succinyl casein.
  • the solution is sent on to filtration,
  • the filtered solution is loaded in a glaze reactor equipped with a fast shaker and with a pH detector, wherein over a period of about 30-40 minutes a solution of 6.4 ferrous chloride in 66 litres of water is added, up until a pH of
  • the reactor can be washed with distilled water to recuperate any product remaining in the reactor.
  • step c) The iron succinyl casein complex obtained in step c) subjected to damp granulation is then loaded into a steel reactor where 350 litres of distilled water have been loaded.
  • the mixture is shaken for about 30 minutes to dissolve the salts and other water-soluble impurities and is then filtered.
  • Step e) Clarification and spray-drying The washed and filtered and possibly granulated product is loaded into a steel shaker reactor into which 330 litres of distilled water have been loaded, and stirred for about an hour, whereupon 3.3 litres of a 15% caustic soda solution are added up until a pH of about 6 is reached.
  • the preservatives are added to this suspension, for example 1.46 kg of methylparaben in 5.5 litres of water and 0.4 kg of propylparaben in 5.5 litres of water.
  • This solution is then filtered in a small press-plate filter for clarification.
  • the solution obtained is pre-heated to a temperature comprised between 40 and 60 degrees C and is sent on to a spray-drier, which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets.
  • a spray-drier which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets.
  • the desired product is obtained in the form of a sodium salt having a granulometry which enables it to be easily dissolved in water for the preparation of the final liquid pharmaceutical forms.
  • the clarified solution according to the process described in step e) can be sent on for freeze-drying instead of spray-drying.
  • the product obtained with high qualitative characteristics and with a very low insoluble residue of ⁇ 0.3% is however more expensive to produce than the product obtained using spray-drying.
  • Example no. 2 Production of iron protein acetyl aspartate complex.
  • step a) The solution obtained in step a) is transferred into a glaze reactor, equipped with a high-speed stirrer to keep the solution homogeneous. This solution is slowly added to with 17-18 litres of HCl at 15% w/v up until a pH of about 3 is obtained. On reaching the correct pH addition of acid is stopped and a precipitate without salt and water-soluble impurities is obtained.
  • step c) Filtration and granulation.
  • the acetyl aspartate casein obtained in step b) is collected by filtration and washed with distilled water.
  • the product gathered from the filter is generally conformed in compact blocks which dissolve with difficulty.
  • damp granulation e.g. in a Viani granulator
  • the granulate is placed in a stainless steel reactor in which 200 litres of distilled water have been placed, and the mixture is shaken until a homogeneous suspension is obtained, to which about 9 litres of caustic soda at 15% w/v are added up until a pH of 8-9 is reached. During the final stage the suspension is stirred for about 6 hours in order to obtain an almost- complete dissolving of the acetyl aspartate casein. The solution is sent on to filtration.
  • the filtered solution is loaded in a glaze reactor equipped with a fast stirrer and with a pH detector, wherein over a period of about 30-40 minutes a solution of 6.0 ferrous chloride in 60 litres of water is added, up until a pH of 3 is reached. When the pH of 3 is reached, addition of ferrous chloride is stopped. An iron acetyl aspartate complex precipitate is obtained, which is slowly shaken for about 30 minutes, whereupon the complex is filtered to gather the product thus obtained.
  • the reactor can be washed with distilled water to recuperate any product remaining in the reactor.
  • step c) The iron acetyl aspartate complex obtained in step c) subjected to damp granulation is then loaded into a steel reactor where 300 litres of distilled water have been loaded.
  • the mixture is shaken for about 30 minutes to dissolve the salts and other water-soluble impurities and is then filtered.
  • the washed and filtered and possibly granulated product is loaded into a steel anchor stirrer reactor into which 300 litres of distilled water have been loaded, and shaken for about an hour, whereupon 3.0 litres of a 15% caustic soda solution are added up until a pH of about 6 is reached.
  • the preservatives are added to this suspension, for example 1.34 kg of methylparaben in 5.0 litres of water and 0.36 kg of propylparaben in 5.0 litres of water.
  • the solution obtained is pre-heated to a temperature comprised between 40 and 60 degrees C and is sent on to a spray-drier, which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets.
  • a spray-drier which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets.
  • the desired product is obtained in the form of a sodium salt having a granulometry which enables it to be easily dissolved in water for the preparation of the final liquid pharmaceutical forms.
  • the clarified solution according to the process described in step e) can be sent on for freeze-drying instead of spray-drying.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The process described in the present patent application is differentiated from the prior art by the fact of the elimination of the drying stage of the final product, with machines requiring exposure of the product for prolonged periods to high temperatures, which thus obtains the product directly in the form of water-soluble sodium salt, which is the salt used in the final pharmaceutical mixture, thus avoiding the need to re-dissolve the product by addition of caustic soda, which adds to the danger of damaging it. Solublising apparatus is also required to guarantee an optimal and constant pH for the solution destined to be used to fill phials; the present invention does not require this apparatus. Also, no use of special pumps is required - not always readily available in the chemical industry and requiring high levels of maintenance.

Description

Description
A Process for Producing Iron succinyl casein and acetyl-aspartate iron casein Complexes and Use thereof in Pharmaceutical Mixtures.
Technical Field
The aim of the invention is to provide an industrial process for production of iron succinyl casein and acetyl-aspartate iron casein based complexes in which the substance is little exposed to pH and temperature conditions which might damage the protein's secondary, tertiary and quaternary chemical- physical characteristics, as well as facilitating preparation of the relative liquid pharmaceutical formulations and their appearance as clear solutions. The process is also easy to realise industrially and is simpler with respect to other known processes. Background Art Iron plays a fundamental role in both human and animal physiology.
Its role and the lack of it in some pathological conditions make it important to administer iron-based substances in order to complete or replace quantities thereof normally assumed in the course of a normal diet. Unfortunately many substances used in medical practice include relevant problems related to side effects.
Two pharmaceutical substances which have demonstrated fewer side effects are iron succinyl casein and acetyl-aspartate iron casein. Their success in some countries demonstrates the favourable reaction of the medical profession as well as of the patients. In European patent application no. 98124195.3 (Bonifacio, Massardo, Di Leo), an improved process is described for the production of iron succinyl casein with respect to the process described in patent no. GB-A-2115821. However the process includes the use of machines and process conditions which are very specific and which limit productivity too, as they require realisation times which are very long, as well as continuous checks to be sure that temperature, pH and defined residual pressure parameters are all adhered to. Further, by exposing the product for long times to non-optimal pH and temperatures for maintaining its protein structure, it is easy to damage the quality of the pharmaceutical substance with, for example, the formation of insoluble residue, as evidenced in European patent no. 98124195.3. Also, Italian patent no. 1207996, relating to the production of acetyl-aspartate iron casein exhibits the same drawbacks as above for the iron succinyl casein complex.
The process described in the present patent application is differentiated from the prior art by the fact of the elimination of the drying stage of the final product, with machines requiring exposure of the product for prolonged periods to high temperatures, which thus obtains the product directly in the form of water-soluble sodium salt, which is the salt used in the final pharmaceutical mixture, thus avoiding the need to re-dissolve the product by addition of caustic soda, which adds to the danger of damaging it. Solublising apparatus is also required to guarantee an optimal and constant pH for the solution destined to be used to fill phials; the present invention does not require this apparatus. Also, no use of special pumps is required - pumps which may not always be readily available in the chemical industry and requiring high levels of maintenance. Disclosure of Invention
The invention relates to a process for obtaining iron succinyl casein and acetyl-aspartate iron casein complexes, obtained by reaction of high-quality casein, for pharmaceutical use, with succinyl anhydride and iron chloride or with acetyl aspartic anhydride and iron chloride.
The process described for obtaining iron complexes with succinyl casein and acetyl-aspartate casein is characterised in that: a) the succinyl casein, iron succinyl casein, acetyl-aspartate casein and iron acetyl-aspartate casein obtained are damp-granulated when they are destined for further dissolving, to facilitate the dissolving process in water with addition of caustic soda with a pH of below eleven. b) The purified iron succinyl casein and acetyl-aspartate iron casein complexes obtained are dried using a spray drier.
The spray-drier is a frequently used machine in the food industry, especially in milk-derivative products which include casein.
The spray-drier technique is used in the pharmaceutical industry whenever a heat-sensitive product is to be dried.
In spray-drying, the solution containing the iron casein complexes is reduced to very small droplets which are then dried by means of hot air which is directed onto the small droplets.
The powders thus obtained are collected in a separator centrifuge and then in a suitable container.
Alternatively, the solution containing the iron casein complexes can be freeze-dried. Freeze drying is obviously very gentle in terms of exposing the product to high temperatures. It is, however, an expensive process and is in general used for high-value products, almost always destined for use in the form of injections. Overall the process of synthesis of the iron succinyl casein and iron acetyl- aspartate casein complex comprises the following steps:
1) The casein of suitable purity for a pharmaceutical process, dissolved with water with an addition of caustic soda having a pH of less than eleven, preferably less than 9, is made to react with succinyl anhydride or acetyl-aspartate anhydride in order to obtain succinyl casein or acetyl-aspartate casein which are precipitated for acidification at a pH of between 2.5 and 3.
2) The succinyl casein and acetyl-aspartate casein obtained in step 1 are dissolved in water with addition of caustic soda with a pH of less than
11, preferably less than 9, and are then reacted with iron chloride to obtain the iron succinyl casein and iron acetyl-aspartate casein complexes which precipitate from the solution when a pH of 2.5 to 3 is reached. 3) The complexes obtained in step 2 can be purified by pulping in water or alternatively by dissolving in water and caustic soda at a pH of less than 1 1, followed by a further precipitation at pH 2.5 to 3. The iron succinyl casein or iron acetyl-aspartate casein complexes are then dissolved in water with the help of caustic soda at a pH of less than 11 , preferably less than 9, and are then added to by suitable preservatives
(e.g. parabens) before being sent on to a spray-drier, where a powder is obtained that is directly usable for the pharmaceutical mixtures it is destined for. Alternatively the solution can be sent on to a freeze-drying process. The product has an iron complex content of between 4.8 and 5.5%, calculated by weight of dry substance. For the complete characterisation of the product, see the data included in examples nos. 1 and 2. The described process, apart from being simpler than those described in the prior art, enables a product which is especially free of poorly-water-solvent parts, mainly due to denaturing of the protein structure. Example no. 1. Production of iron succinyl casein complex. Step a) Succinylation of casein
In a stainless steel reactor with special stirrer (preferably an anchor stirrer) and pH detector, 300 litres of de-ionized, microbiologically pure water added to by 22 Kg of casein suitable for food or pharmaceutical use are mixed and shaken to obtain a homogeneous suspension. 2.2 litres of caustic soda at 15% w/v are added to this over a period of about 20-30 minutes up until a pH of about 8 is reached. To this solution are added 6.6 Kg of succinyl anhydride and about 16 litres of a 15% caustic soda solution, maintaining pH of between 7.5 and 9. The solution obtained is left to rest for between 1 and 2 hours. The reaction is conducted at a temperature of between 20 and 25 degrees Celsius. Step b) Precipitation of the succinyl casein
The solution obtained in step a) is transferred into a glaze reactor, equipped with a high-speed shaker to keep the solution homogeneous. This solution is slowly added to with 16-17 litres of HCl at 15% w/v up until a pH of about 3 is obtained. On reaching the correct pH addition of acid is stopped and a precipitate without salt and water-soluble impurities is obtained. Step c) Filtration and granulation.
The succinyl casein obtained in step b) is collected by filtration and washed with distilled water. The product gathered from the filter is generally conformed in compact blocks which dissolve with difficulty. To facilitate dissolving damp granulation (e.g. in a Viani granulator) of the filtered product is recommended.
The granulate is placed in a stainless steel reactor in which 300 litres of distilled water have been placed, and the mixture is shaken until a homogeneous suspension is obtained, to which about 7 litres of caustic soda at 15% w/v are added up until a pH of 8-9 is reached. During the final stage the suspension is shaken for about 6 hours in order to obtain an almost- complete dissolving of the succinyl casein.
The solution is sent on to filtration, The filtered solution is loaded in a glaze reactor equipped with a fast shaker and with a pH detector, wherein over a period of about 30-40 minutes a solution of 6.4 ferrous chloride in 66 litres of water is added, up until a pH of
3 is reached.
When the pH of 3 is reached, addition of ferrous chloride is stopped. An iron succinyl casein complex precipitate is obtained, which is slowly shaken for about 30 minutes, whereupon the complex is filtered to gather the product thus obtained.
The reactor can be washed with distilled water to recuperate any product remaining in the reactor. Step d) Purification of the iron succinyl casein complex.
The iron succinyl casein complex obtained in step c) subjected to damp granulation is then loaded into a steel reactor where 350 litres of distilled water have been loaded.
The mixture is shaken for about 30 minutes to dissolve the salts and other water-soluble impurities and is then filtered.
Step e) Clarification and spray-drying. The washed and filtered and possibly granulated product is loaded into a steel shaker reactor into which 330 litres of distilled water have been loaded, and stirred for about an hour, whereupon 3.3 litres of a 15% caustic soda solution are added up until a pH of about 6 is reached. The preservatives are added to this suspension, for example 1.46 kg of methylparaben in 5.5 litres of water and 0.4 kg of propylparaben in 5.5 litres of water.
About another 1 litre of 15% caustic soda solution is added to this suspension up until a pH of between 8 and 9 is reached, During the addition, stirring is continued for about 6 hours until the iron complex is almost completely dissolved.
This solution is then filtered in a small press-plate filter for clarification.
The solution obtained is pre-heated to a temperature comprised between 40 and 60 degrees C and is sent on to a spray-drier, which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets. Thus the desired product is obtained in the form of a sodium salt having a granulometry which enables it to be easily dissolved in water for the preparation of the final liquid pharmaceutical forms. Step e')
The clarified solution according to the process described in step e) can be sent on for freeze-drying instead of spray-drying.
The product obtained with high qualitative characteristics and with a very low insoluble residue of <0.3% is however more expensive to produce than the product obtained using spray-drying.
Step f) Product characteristics.
- the iron succinyl casein complex - appearance: brown granular powder with slight milky odour; tasteless
- humidity < 5%
- solubility: soluble in purified H2O
- pH = 7.5-9.0 - free iron:< 50ppm
- total iron: 4.8-5.4%
- proteins: >72.5%
- succinyl acid total: 7-9.5%
- Free succinyl acid: < 1.5% - Chlorides: <2.5%
- Methylparabens: <3% in weight
- Propylparabens: <1% in weight
- Bacterial content: <103 UFC/g
- Mold and yeast content: <102 UFC/g - Insoluble residue:<0.2-0.3%
Example no. 2. Production of iron protein acetyl aspartate complex.
Step a) Preparation of the acetyl aspartate casein
In a stainless steel reactor with sufficient shaker and pH detector, preferably an anchor stirrer, 200 litres of de-ionized, microbiologically pure water added to by 20 Kg of casein suitable for food or pharmaceutical use. The mixture is shaken to obtain a homogeneous suspension. 2.5 litres of caustic soda at 15% w/v are added to this over a period of about 20-30 minutes up until a pH of about 8 is reached. To this solution are added 5.0 Kg of succinyl anhydride and about 15.8 litres of a 15% caustic soda solution, maintaining pH at between 7.5 and 9. The solution obtained is left to rest for between 1 and 2 hours. The reaction is conducted at a temperature of between 20 and 25 degrees Celsius. Step b) Precipitation of the acetyl aspartate casein
The solution obtained in step a) is transferred into a glaze reactor, equipped with a high-speed stirrer to keep the solution homogeneous. This solution is slowly added to with 17-18 litres of HCl at 15% w/v up until a pH of about 3 is obtained. On reaching the correct pH addition of acid is stopped and a precipitate without salt and water-soluble impurities is obtained. Step c) Filtration and granulation. The acetyl aspartate casein obtained in step b) is collected by filtration and washed with distilled water.
The product gathered from the filter is generally conformed in compact blocks which dissolve with difficulty. To facilitate dissolving damp granulation (e.g. in a Viani granulator) of the filtered product is recommended.
The granulate is placed in a stainless steel reactor in which 200 litres of distilled water have been placed, and the mixture is shaken until a homogeneous suspension is obtained, to which about 9 litres of caustic soda at 15% w/v are added up until a pH of 8-9 is reached. During the final stage the suspension is stirred for about 6 hours in order to obtain an almost- complete dissolving of the acetyl aspartate casein. The solution is sent on to filtration.
The filtered solution is loaded in a glaze reactor equipped with a fast stirrer and with a pH detector, wherein over a period of about 30-40 minutes a solution of 6.0 ferrous chloride in 60 litres of water is added, up until a pH of 3 is reached. When the pH of 3 is reached, addition of ferrous chloride is stopped. An iron acetyl aspartate complex precipitate is obtained, which is slowly shaken for about 30 minutes, whereupon the complex is filtered to gather the product thus obtained. The reactor can be washed with distilled water to recuperate any product remaining in the reactor.
Step d) Purification of the iron acetyl aspartate complex.
The iron acetyl aspartate complex obtained in step c) subjected to damp granulation is then loaded into a steel reactor where 300 litres of distilled water have been loaded.
The mixture is shaken for about 30 minutes to dissolve the salts and other water-soluble impurities and is then filtered.
Step e) Clarification and spray-drying.
The washed and filtered and possibly granulated product is loaded into a steel anchor stirrer reactor into which 300 litres of distilled water have been loaded, and shaken for about an hour, whereupon 3.0 litres of a 15% caustic soda solution are added up until a pH of about 6 is reached.
The preservatives are added to this suspension, for example 1.34 kg of methylparaben in 5.0 litres of water and 0.36 kg of propylparaben in 5.0 litres of water.
About another 1 litre of 15% caustic soda solution is added to this suspension up until a pH of between 8 and 9 is reached.
During the addition, stirring is continued for about 6 hours until the iron complex is almost completely dissolved. This solution is then filtered in a small press plate filter for clarification.
The solution obtained is pre-heated to a temperature comprised between 40 and 60 degrees C and is sent on to a spray-drier, which uses filtered and heated air at a temperature of about 170-200 degrees C to dry the solution which has been atomised into small droplets. Thus the desired product is obtained in the form of a sodium salt having a granulometry which enables it to be easily dissolved in water for the preparation of the final liquid pharmaceutical forms. Step e')
The clarified solution according to the process described in step e) can be sent on for freeze-drying instead of spray-drying.
The product obtained with high qualitative characteristics and with a very low insoluble residue of <0.3% is however more expensive to produce than the product obtained using spray-drying. Step f) Product characteristics.
- iron acetyl aspartate complex
- appearance: brown granular powder with slight milky odour; tasteless - humidity < 5%
- solubility: soluble in purified H2O
- pH = 7.5-9.0
- free iron:< 50ppm
- total iron: 4.8-5.4% - proteins: >72.5%
- n-acetyl aspartic acid total: 7-9.5%
- Free n- acetyl aspartic acid: < 1.8%
- Aspartic acid <0.2%
- Chlorides: <2.5% - Methylparabens: <3% in weight
- Propylparabens: <1% in weight
- Bacterial content: <103 UFC/g MoId and yeast content: <102 UFC/g Insoluble residue:<0.2-0.3%

Claims

Claims.
1). A process for producing an iron complex (III) with succinyl casein, obtained by reaction of casein with succinyl anhydride and a subsequent reaction of the succinyl casein obtained with ferrous chloride, wherein granulation of the succinyl anhydride and the iron succinyl casein is performed to facilitate dissolving thereof; the sodium salt iron succinyl casein is dried using a spray-drying or freeze-drying technique.
2). The process of claim 1, wherein addition of succinyl anhydride to the casein solution is performed with a pH of between 6 and 9.
3). The process of claim 1, wherein the succinyl casein obtained is precipitated by acidification at a pH comprised between 1 and 4.
4). The process of claim 1, wherein the reaction between the succinyl casein and the ferrous chloride solution is performed until a pH of 2.5-3 is obtained.
5). The process of claim 1, wherein the iron succinyl casein solution is clarified before being sent on for spray-drying or freeze-drying.
6). A process for producing an iron complex (III) with acetyl aspartic casein, obtained by reaction of casein with acetyl aspartic anhydride and following reaction of the acetyl aspartic casein obtained with ferrous chloride, wherein granulation of the acetyl aspartic casein and the iron acetyl aspartic casein is performed to facilitate dissolving thereof; the sodium salt iron succinyl casein is dried using a spray-drying or freeze-drying technique.
7). The process of claim 6, wherein addition of acetyl aspartic anhydride to the casein solution is performed with a pH of between 6 and 9.
8). The process of claim 6, wherein the acetyl aspartic casein obtained is precipitated by acidification at a pH comprised between 1 and 4. 9). The process of claim 6, wherein the reaction between the acetyl aspartic casein and the ferrous chloride solution is performed until a pH of 2.5-3 is obtained.
10). The process of claim 6, wherein the iron acetyl aspartic casein solution is clarified before being sent on for spray-drying or freeze-drying.
PCT/IB2005/002199 2004-07-29 2005-07-20 A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures WO2006021843A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05761444A EP1776382B1 (en) 2004-07-29 2005-07-20 A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures
DE602005011451T DE602005011451D1 (en) 2004-07-29 2005-07-20 PROCESS FOR THE PREPARATION OF ICE SENSORY CASEIN AND ACETYLASPARTATE IRON CASEIN COMPLEXES AND THEIR USE IN PHARMACEUTICAL MIXTURES

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMO2004A000200 2004-07-29
IT000200A ITMO20040200A1 (en) 2004-07-29 2004-07-29 PROCESS FOR THE PRODUCTION OF SUCCINYLCASEIN IRON AND CASEIN ACETYL IRON ASPARTILATED AND USED IN THE RELEVANT PHARMACEUTICAL COMPOSITIONS.
ITMOV0084 2004-10-22

Publications (1)

Publication Number Publication Date
WO2006021843A1 true WO2006021843A1 (en) 2006-03-02

Family

ID=35967190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002199 WO2006021843A1 (en) 2004-07-29 2005-07-20 A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures

Country Status (6)

Country Link
EP (1) EP1776382B1 (en)
AT (1) ATE416193T1 (en)
DE (1) DE602005011451D1 (en)
ES (1) ES2317270T3 (en)
IT (1) ITMO20040200A1 (en)
WO (1) WO2006021843A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065812A1 (en) * 2005-12-06 2007-06-14 Vifor (International) Ag Process for the preparation of ferri-succinylcasein
WO2012001712A1 (en) * 2010-06-30 2012-01-05 Italfarmaco S.P.A. Iron (iii) caseinsuccinylate and method for the preparation thereof
EP3034512A1 (en) 2014-12-19 2016-06-22 Ioulia Tseti A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
CN108264546A (en) * 2016-12-30 2018-07-10 河北凯盛医药科技有限公司 Succinyl casein-ferrous iron and its preparation method and application
GR1009589B (en) * 2018-04-05 2019-09-11 Ιουλια Κλεωνος Τσετη Pharmaceutical anemia-treating formula kept in two separate parts of a container - 3-valent iron with n-acetyl-l-aspartic casein and pentahydrate calcium folinate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493829A (en) * 1982-03-02 1985-01-15 Italfarmaco S.P.A. Bio-available succinylated protein-iron derivatives which do not cause gastric lesions, method of preparation and related pharmaceutical compounds
EP0243322A2 (en) * 1986-03-18 1987-10-28 Magis Farmaceutici S.P.A. Compounds containing bioavailable iron, process for their preparation and pharmaceutical compositions containing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493829A (en) * 1982-03-02 1985-01-15 Italfarmaco S.P.A. Bio-available succinylated protein-iron derivatives which do not cause gastric lesions, method of preparation and related pharmaceutical compounds
EP0243322A2 (en) * 1986-03-18 1987-10-28 Magis Farmaceutici S.P.A. Compounds containing bioavailable iron, process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CREMONESI P ET AL: "CHEMICAL AND BIOLOGICAL CHARACTERIZATION OF IRON-PROTEIN SUCCINYLATE (ITF 282)", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY AND TOXICOLOGY, DUSTRI- VERLAG FEISTLE, DEISENHOFEN/MUENCHEN, DE, vol. 31, no. 1, January 1993 (1993-01-01), pages 40 - 51, XP001012289, ISSN: 0174-4879 *
CREMONESI P ET AL: "Iron derivatives of modified milk protein.", ARZNEIMITTEL-FORSCHUNG. 1984, vol. 34, no. 9, 1984, pages 948 - 952, XP001207730, ISSN: 0004-4172 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065812A1 (en) * 2005-12-06 2007-06-14 Vifor (International) Ag Process for the preparation of ferri-succinylcasein
AU2006324080B2 (en) * 2005-12-06 2012-04-12 Vifor (International) Ag Process for the preparation of ferri-succinylcasein
WO2012001712A1 (en) * 2010-06-30 2012-01-05 Italfarmaco S.P.A. Iron (iii) caseinsuccinylate and method for the preparation thereof
RU2533826C2 (en) * 2010-06-30 2014-11-20 Италфармако С.П.А. Casein succinylate of iron (iii) and method of its production
EP3034512A1 (en) 2014-12-19 2016-06-22 Ioulia Tseti A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
WO2016096203A1 (en) * 2014-12-19 2016-06-23 Ioulia Tseti A process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
AU2015365885B2 (en) * 2014-12-19 2018-11-15 Ioulia Tseti A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
EA031968B1 (en) * 2014-12-19 2019-03-29 Юлия Цети Process for producing iron(iii) complex with n-acetyl-aspartylated casein and use thereof in pharmaceutical compositions
CN108264546A (en) * 2016-12-30 2018-07-10 河北凯盛医药科技有限公司 Succinyl casein-ferrous iron and its preparation method and application
GR1009589B (en) * 2018-04-05 2019-09-11 Ιουλια Κλεωνος Τσετη Pharmaceutical anemia-treating formula kept in two separate parts of a container - 3-valent iron with n-acetyl-l-aspartic casein and pentahydrate calcium folinate

Also Published As

Publication number Publication date
ATE416193T1 (en) 2008-12-15
EP1776382B1 (en) 2008-12-03
EP1776382A1 (en) 2007-04-25
DE602005011451D1 (en) 2009-01-15
ES2317270T3 (en) 2009-04-16
ITMO20040200A1 (en) 2004-10-29

Similar Documents

Publication Publication Date Title
JPH0458946B2 (en)
EP1776382B1 (en) A process for producing iron succinyl casein and acetyl-aspartate iron casein complexes and use thereof in pharmaceutical mixtures
AU2006324080B2 (en) Process for the preparation of ferri-succinylcasein
JP2000128880A (en) Purification and crystallization of riboflavin
KR100563361B1 (en) Ferro-succinyl casein complex, preparation method thereof and pharmaceutical composition containing same
JPH04261176A (en) Process for purification of ribofulavine produced by enzymic process
CN108976142A (en) A kind of preparation method of ASPARTIC ACID calcium
KR100720202B1 (en) Process for preparing spray granules containing riboflavin
AU769849B2 (en) L-carnitine agent
JPH0393753A (en) Production of alpha-amino acid
EP3034512B1 (en) A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions
JP2945433B2 (en) Extraction method of squid soft shell
JPH04341193A (en) Production of peptide or its salt
JP2004526805A (en) Method for producing amorphous cilastatin sodium
JPH11180948A (en) Production of s-(1,2-dicarboxyethyl)glutathione
KR20060102373A (en) Manufacturing method of calcium binding amino acid
JP3093109B2 (en) Method for producing 1-aza-6-chloro-8-methyl-4-thio- (3H) -naphthalen-2-one
CN117866071A (en) Preparation method of protein iron succinate
SU827068A1 (en) Method of obtaining lydasa
JPH0380052A (en) Production of plasma protein
JP2004514713A (en) Method for producing phenylene-bis-benzimidazole-tetrasulfonic acid disodium salt
OA18236A (en) A process for producing iron (III) casein Nacetyl-aspartylated complexes and use thereof in pharmaceutical compositions.
JPH04112850A (en) Production of metallic salt of ether carboxylic acid
JPS6061553A (en) Preparation of tyrosine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005761444

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005761444

Country of ref document: EP